Emerging efforts for discovering new biomarkers of liver disease and hepatotoxicity

Biomarkers in Medicine

Volumn 8, Issue 2, 2014, Pages 143-146

  Hong, Huixiao ^a   Tong, Weida ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

biomarkers; discovery; hepatotoxicity; liver disease

Indexed keywords

ACETAMINOPHEN; BIOLOGICAL MARKERS; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER DISEASES; METABOLOMICS;

EID: 84894316876     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.156     Document Type: Review

References (17)

1. Hong H, Goodsaid F, Shi L, Tong W. Molecular biomarkers: a US FDA effort. Biomarkers Med. 4, 215-225 (2010).
2. Shi Q, Hong H, Senior J, Tong W. Biomarkers for drug-induced liver injury. Expert Rev. Gastroenterol. Hepatol. 4(2), 225-234 (2010).
3. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment inhepatotoxicity by drugs and dietary supplements. Br. J. Clin. Pharmacol. 66, 758-766 (2008).
4. Lee WM. Etiologies of acute liver failure. Semin. Liver Dis. 28, 142-152 (2008).
5. Chen C, Krausz KW, Shah YM et al. Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem. Res. Toxicol. 22(4), 699-707 (2009).
6. Bhattacharyya S, Yan K, Pence L et al. Targeted liquid chromatography-mass spectrometry analysis of serum acylcarnitines in acetaminophen toxicity in children. Biomarkers Med. 8(2), 147-159 (2014).
7. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nature Rev. Genet. 5, 522-531 (2004).
8. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin. Chem. 55, 623-631 (2009).
9. Nana-Sinkam SP, Croce CM. MicroRNAs as therapeutic targets in cancer. Trans. Res. 157, 216-225 (2011).
10. Liu J, Jennings S, Tong W, Hong H. Next-generation sequencing for profiling expression of miRNAs: technical progress and applications in drug development. J. Biomed. Sci. Eng. 4, 666-676 (2011).
11. Wang Y, Chen T, Tong W. miRNAs and their application in drug-induced liver injury. Biomarkers Med. 8(2), 161-172 (2014).
12. Laterza OF, Lim L, Garrett-Engele PW et al. Plasma microRNAs as diagnostically sensitive and specific biomarkers of tissue injury. Clin. Chem. 55(11), 1977-1983 (2009).
13. Persson M, Loye AF, Mow T, Hornberg JJ. A high content screening assay to predict human drug-induced liver injury during drug discovery. J. Pharmacol. Toxicol. Methods 68(3), 302-313 (2013).
14. Li AP. Biomarkers and human hepatocytes. Biomarkers Med. 8(2), 173-183 (2014).
15. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467-470 (1995).
16. Hebels DGA, Jetten MJA, Aerts HJW et al. Evaluation of database-derived pathway development for enabling biomarker discovery for hepatotoxicity. Biomarkers Med. 8(2), 185-200 (2014).
17. Chen M, Bisgin H, Tong L et al. Toward predictive models for drug-induced liver injury in humans: are we there yet? Biomarkers Med. 8(2), 201-213 (2014).